Insmed delayed Germany. Pfizer struck a manufacturing deal with the White House. Here’s what the pattern tells us.
In our first article, we mapped the mechanics of Most-Favored Nation (MFN) pricing and the highest-exposure areas it creates. Now the question shifts from what is happening to what to do about it, and the answer is already visible in how leading manufacturers are moving.
As of September 2026, at least 26 major pharmaceutical companies hold MFN agreements positioned for participation once GENEROUS terms are finalized. Companies are not waiting for final rules to act. They are already adjusting launch sequencing, shifting toward confidential pricing mechanisms, and in some cases restructuring where and how they enter reference markets.
The Pattern Emerging Across the Industry
Three strategic responses stand out. Launch sequencing discipline: manufacturers are modeling historical launch-delay patterns in IRP-sensitive markets before committing to a sequence, and in some cases deliberately delaying entry into markets that serve as reference-basket anchors. Confidential mechanisms, used carefully: managed entry agreements and volume-based rebates protect public list prices, but leading companies treat this as a partial defense, not a complete one, since regulators increasingly have access to net price data and confidential agreements may not prevent retrospective adjustments. Voluntary agreements as strategic positioning: Pfizer’s agreement with the Trump Administration, tying MFN-aligned pricing to manufacturing commitments and tariff relief, shows manufacturers choosing to engage proactively rather than wait for mandatory frameworks.
Why Response Speed Requires Data, Not Just Strategy
Here is what separates companies executing these strategies well from those struggling: data readiness. Every one of these responses depends on knowing your exposure before you act, not after.
This is where most organizations fall short. Data on realized net prices remains incomplete or lagged. Many companies cannot quickly answer which products, by U.S. channel, actually fall under GENEROUS, GLOBE, or GUARD exposure criteria. The gap is not strategic thinking. Most pricing leaders understand the mechanics well. The gap is operational: fragmented ERPs and quarterly manual updates cannot support decisions that need to be modeled in days, not months.
Closing that gap is not a matter of hiring more analysts or building another spreadsheet template. It requires a different category of technology, purpose-built for exactly this kind of cross-border pricing complexity. The manufacturers making headlines for their MFN response did not arrive at those decisions overnight. They invested in the capability to see exposure coming and the discipline to act on it quickly.
That combination, not any single tactic, is what separates companies protecting value from those absorbing avoidable losses. The question is what that capability actually looks like in practice, and how fast an organization can stand it up.
